SCHEMBL2028171

SCHEMBL2028171

CC(=O)OCC(COP(=O)(O)OCCNC(=O)CCCCCNC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)OC(C)=O.CCN(CC)CC

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PLCD1 P51178 1/20 0.55
▸ F2 P00734 1/20 0.53
▸ PRSS1 P07477 1/20 0.53
▸ PRSS2 P07478 1/20 0.53
▸ PRSS3 P35030 1/20 0.53
▸ TPSAB1 Q15661 1/20 0.53
▸ CNR2 P34972 2/20 0.51
▸ CNR1 P21554 3/20 0.51
▸ TDP1 Q9NUW8 2/20 0.49
▸ FOLH1 Q04609 3/20 0.46
▸ HPSE Q9Y251 1/20 0.44
▸ CAPN1 P07384 2/20 0.43
▸ ITGB1 P05556 1/20 0.42
▸ ITGA4 P13612 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ HSP90AB1 P08238 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486900 0.98 F2 (0.53) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL3614161 0.96 PLCD1 (0.59) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL486814 0.94 PLCD1 (0.56) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL1270689 0.91 PLCD1 (0.44) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL487698 0.91 PLCD1 (0.44) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL2028172 0.87 F2 (0.51) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL20500226 0.86 PLCD1 (0.48) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL12989865 0.86 CNR2 (0.68) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL30165784 0.84 CNR2 (0.66) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL10140249 0.84 CNR2 (0.66) PLCD1F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 — — EP disclosed
US-20200261363-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2020-08-20 — — US disclosed
US-10463616-B2 Lipid construct for delivery of insulin to a mammal SDG, INC. (US) 2019-11-05 — — US disclosed
US-20190054021-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, INC. 2019-02-21 — — US disclosed
EP-3391876-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, Inc. (US) 2018-10-24 — — EP disclosed
US-10004686-B2 Lipid construct for delivery of insulin to a mammal SDG, INC. (US) 2018-06-26 — — US disclosed
EP-1883394-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2018-03-28 — — EP disclosed
US-9034372-B2 Lipid construct for delivery of insulin to a mammal SDG, INC. (US) 2015-05-19 — — US disclosed
US-20150031608-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, INC. 2015-01-29 — — US disclosed
US-20130267462-A1 Lipid Construct for Delivery of Insulin to a Mammal SDG, INC. 2013-10-10 — — US disclosed
US-20110135725-A1 Lipid Construct for Delivery of Insulin to a Mammal SDG, INC. (US) 2011-06-09 — — US disclosed
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL HAVCR2, IFNAR1, IFNG PLCD1 1837/4885F2 2498/4885PRSS1 2887/4885
US-10004686-B2 Lipid construct for delivery of insulin to a mammal INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-20190054021-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-20200261363-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-10463616-B2 Lipid construct for delivery of insulin to a mammal INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-20110135725-A1 Lipid Construct for Delivery of Insulin to a Mammal INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-20150031608-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885
US-20130267462-A1 Lipid Construct for Delivery of Insulin to a Mammal INSR, IAPP, GPR119 PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback